Capricor Therapeutics (CAPR) Tops Q2 EPS by 1c

Capricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.35), $0.01 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $3.97 million versus the consensus estimate of $4.41 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Activist Jana Partners takes 6.3% stake in Alkami Technology, urges sale
• FDA selects seven participants for precheck pilot program to advance U.S. drug manufacturing